M Tomblyn

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
    M Tomblyn
    Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 40:111-8. 2007
  2. pmc Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation
    Marcie Tomblyn
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 14:538-45. 2008
  3. doi request reprint Donor lymphocyte infusions: the long and winding road: how should it be traveled?
    M Tomblyn
    Adult Blood and Marrow Transplant Program, Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 42:569-79. 2008
  4. doi request reprint Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
    V Bachanova
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:237-44. 2009
  5. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
  6. doi request reprint Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation
    Claudio G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:214-22. 2009
  7. pmc Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation
    P Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 44:113-20. 2009
  8. pmc Second hematopoietic stem cell transplantation in myeloid malignancies
    Lisa M Arfons
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Curr Opin Hematol 16:112-23. 2009
  9. ncbi request reprint Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma
    Marcie Tomblyn
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 3:281-94. 2003

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma
    M Tomblyn
    Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 40:111-8. 2007
    ..The poor clinical outcome of patients with difficult mobilization using either method identifies them as a high-risk group who might benefit from alternative therapies...
  2. pmc Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation
    Marcie Tomblyn
    Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 14:538-45. 2008
    ..Modifications to refine patient assignment to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed...
  3. doi request reprint Donor lymphocyte infusions: the long and winding road: how should it be traveled?
    M Tomblyn
    Adult Blood and Marrow Transplant Program, Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 42:569-79. 2008
    ....
  4. doi request reprint Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma
    V Bachanova
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:237-44. 2009
    ....
  5. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
    ..A careful review of existing comorbidities is necessary when considering older patients for HCT...
  6. doi request reprint Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation
    Claudio G Brunstein
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:214-22. 2009
    ..Based on our data, we conclude that a nonmyeloablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with advanced lymphoid malignancies who lack a suitable sibling donor...
  7. pmc Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation
    P Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 44:113-20. 2009
    ..600 microg(*)h/ml in 87-100% of subjects. There appears to be no significant difference in daily MPA exposure when MMF of 3 g/day is divided into two or three equal doses...
  8. pmc Second hematopoietic stem cell transplantation in myeloid malignancies
    Lisa M Arfons
    Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA
    Curr Opin Hematol 16:112-23. 2009
    ..Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation...
  9. ncbi request reprint Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma
    Marcie Tomblyn
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 3:281-94. 2003
    ..Based upon the current literature, hematopoietic stem cell transplant cannot be recommended as first-line therapy in patients with non-Hodgkin's lymphoma outside the setting of a clinical trial...